Observational studyJournal of neurology2026
Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosis.
Observational study in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRetinal layer thinning is associated with disability progression and treatment failure in relapsing multiple sclerosis (RMS). However, the systematic integration of optical coherence tomography (OCT)-derived metrics into a composite measure of treatment response has not yet been evaluated.
methodsWe analyzed two observational cohorts of patients with RMS who newly initiated DMT, received an MRI and OCT at baseline and 12 months, and had ≥ 24 months of clinical follow-up. No evidence of disease activity (NEDA-3/NEDA-3 + OCT) status was assigned at 12 months after DMT. Retinal thinning was defined as a reduction of ≥ 1.0 µm/year peripapillary retinal nerve fiber layer or ≥ 0.5 µm/year ganglion-cell/inner plexiform layer. The primary endpoint was confirmed disability progression occurring after the 12 month NEDA assessment. Both low-efficacy DMT and high-efficacy were included and analyzed jointly, with treatment class entered as a covariate in all models.
resultsOverall, 124 individuals (72% female, mean age 33.1 [SD ± 7.7] years, median EDSS of 2.0 [IQR 0.0-2.5]) were included. Over a median follow-up period of 3.4 years, disability progression was observed in 28 (23%) individuals. Time to and risk of disability progression did not significantly differ between EDA-3 and NEDA-3 (restricted mean survival time [RMST]: 43.4 [SE ± 2.8] vs. 48.1 [SE ± 1.3] months, p = 0.067; adjusted hazard ratio [aHR] 1.52, 95% LL-CI 0.64, p = 0.173). When retinal layer thinning was incorporated, EDA-3 + OCT was associated with a higher risk of future progression (aHR 6.59, 95% LL-CI 2.38, p = 0.005) and shorter time to progression (RMST: 41.9 [SE ± 2.1] vs. 51.9 [SE ± 0.9] months, p < 0.001).
conclusionIncorporating retinal layer thinning into the NEDA-3 framework substantially improves prediction of subsequent disability progression compared with conventional NEDA-3 alone, identifying a subgroup of patients in whom ongoing neurodegeneration appears to drive disability accumulation despite suppressed inflammatory activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.